An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Clinical trial NCT05223920 · COMPLETED

Trial details

NCT number: NCT05223920
Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Thrombocythemia, Essential Primary Myelofibrosis

Start date: 2021-12-15
Primary completion: 2024-08-22
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.